Nasdaq: AGMB · Listed Feb 6, 2026
AgomAb Therapeutics NV IPO
IPO price
$16.00
AgomAb Therapeutics NV (AGMB) priced its IPO at $16.00 a share and has traded on Nasdaq since Feb 6, 2026.
AGMB today$5.70-64.38%since IPO15-min delayed · as of 7:56:07 PM EST on Nov 18, 2026
See the AGMB quoteFirst trading day · Feb 6, 2026
- IPO price
- $16.00
- inside the range of $15 to $17
- First trade
- $14.70
- -8.13% from the IPO price
- First-day last trade
- $14.90
- -6.87% from the IPO price, regular session
- Raise
- $200M
- before the underwriters' option
These numbers are from the first trading day, Feb 6, 2026.
How AGMB did against the market
AGMB against the market, from its first trade at 12:35 ET to the last trade of the session.
- AGMB from its first trade
- +1.36%
- Against the market (QQQ)
- +1.1 pts
AGMB rose 1.4% from its first trade to the last trade of the session. That is 1.1 points better than the market.
Same-day moves do not show that AGMB caused them. The market is QQQ, the Nasdaq-100 ETF.
The debut race
AGMB against other big listings, as the percent change from each stock's own IPO price.
The first 30 trading days. Each point is the last regular-session trade of a day.
The first trading day.
The first trading day.
The IPO scoreboard
AGMB against 6 other big listings: the return from each IPO's own price at the first trade, the close of day 1, day 5, and day 30.
| IPO | Raised | First trade | Day 1 close | Day 1 close, as a bar | Day 5 | Day 30 |
|---|---|---|---|---|---|---|
| AgomAb Therapeutics NV '26 | $200M | -8.13% | -6.87% | -2.31% | -23.19% | |
| Figma '25 | $1.22B | +157.58% | +252.42% | +173.64% | +69.64% | |
| Circle '25 | $1.05B | +122.58% | +168.45% | +278.18% | +622.98% | |
| Reddit '24 | $748M | +38.24% | +47.97% | +69.90% | +40.32% | |
| Arm '23 | $5.23B | +10.00% | +23.76% | +3.63% | -3.06% | |
| Klarna '25 | $1.37B | +30.00% | +16.14% | +13.73% | -7.33% | |
| CoreWeave '25 | $1.5B | -2.50% | +0.02% | +34.32% | +28.42% |
Day 1 is the last regular-session trade of the first day. Day 5 and day 30 are the last trade of the fifth and thirtieth trading day, counting the listing day as day 1. A cell fills in when that day has traded.
The offering
The AgomAb Therapeutics NV IPO offers 12.5M shares to raise $200M, before any underwriters' option.
- Expected price range
- $15 to $17
- IPO price
- $16.00
- Shares offered
- 12.5M
- Money raised
- $200M
- Listing date
- Feb 6, 2026
- Exchange
- Nasdaq
- Security
- ADR
Money raised, against the largest IPOs
- Alibaba '14$21.77B
- Facebook '12$18.41B
- Rivian '21$11.93B
- Uber '19$8.1B
- Arm '23$5.23B
- AgomAb Therapeutics NV$200M
Where AGMB ranks
AgomAb Therapeutics NV's market cap against the largest US-listed companies.
Market cap, against the largest US-listed companies
- AAPL$5.12T
- MSFT$3.77T
- NVDA$3.65T
- GOOGL$3.47T
- AMZN$2.9T
- TSM$1.88T
- AVGO$1.69T
- META$1.58T
- TSLA$1.52T
- BRK.B$1.22T
- AGMB$286.62M
AGMB news
The latest news and headlines about AgomAb Therapeutics NV (AGMB).
- Agomab Announces Results of Annual General MeetingneutralGlobeNewswire Inc.· May 27, 2026
- Agomab Reports Full Year 2025 Financial Results and Confirms 2026 OutlookpositiveGlobeNewswire Inc.· Apr 23, 2026
- Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary FibrosispositiveGlobeNewswire Inc.· Mar 26, 2026
- Agomab Announces Closing of Initial Public OfferingpositiveBenzinga· Feb 9, 2026
Filings and the company
What AgomAb Therapeutics NV has disclosed to the SEC, and the basic facts about the listing.
8-K filings
Material events that AgomAb Therapeutics NV discloses to the SEC on Form 8-K.
No 8-K filings yet. A filing appears here after AgomAb Therapeutics NV files it with the SEC.
About AgomAb Therapeutics NV
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
- Ticker
- AGMB
- Exchange
- Nasdaq
- Market
- stocks
- Type
- ADRC
- Currency
- USD
- Employees
- 62
- Listed
- Feb 6, 2026
- Security
- ADR
Frequently asked questions
What was the AgomAb Therapeutics NV IPO price?
$16.00 a share.
When did AgomAb Therapeutics NV go public?
AgomAb Therapeutics NV listed on Nasdaq on Feb 6, 2026 under the ticker AGMB.
How much did the AgomAb Therapeutics NV IPO raise?
$200M, before any underwriters' option.
How did AgomAb Therapeutics NV open on its first day?
AGMB first traded at $14.70, -8.13% from the IPO price of $16.00.
How did AGMB close on its first day?
Its last regular-session trade was $14.90, -6.87% from the IPO price of $16.00.
What was the AGMB first-day trading range?
$12.66 to $15.49 in the regular session.
How many AGMB shares traded on the first day?
2.24M shares in the regular session.
How many shares did AgomAb Therapeutics NV sell in its IPO?
12.5M shares.
How did AGMB do against the market on its first day?
AGMB rose 1.4% from its first trade to the last trade of the session. That is 1.1 points better than the market (QQQ, the Nasdaq-100 ETF).
What exchange is AGMB listed on?
AgomAb Therapeutics NV lists on Nasdaq under the ticker AGMB.
Build with Massive
Get the AGMB data behind this page
| What the page shows | Endpoint |
|---|---|
| Offering terms and dates | /vX/reference/ipos |
| Price | /v3/snapshot |
| Chart, VWAP, and the market comparison | /v2/aggs/ticker/AGMB/range/5/minute |
| Market cap | /v3/reference/tickers/AGMB |
| News | /v2/reference/news |
| Filings | /vX/disclosures |
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.